department of immunolgy
Head: Professor Nina Ivanoska, DSc
Tel: (+359 2) 979 31 95
E-mail:
staff
Laboratory of Infectious Immunology and Inflammation
Head: Professor Nina Ivanoska, DSc
Tel: (+359 2) 979 31 95
E-mail:
Assist. Professor Valeriya Gyurkovska, PhD,
Assist. Professor Tsvetanka Stefanova, PhD,
PhD student Petya Ganova,
Petya Stoyanova, VMD, Research Assistant
Main research topics
Bacterial and Fungal infections, Arthritis, Osteoarthritis, Complement System
Most important results
- A strand of our work characterizes the antiinflammatoryaction of tyrosine kinase inhibitortyrphostin in models of sepsis, particularly via STAT signaling.
- Our data proved that properdin appeared to have a protective role in the processes of joint erosion which suggest that alternative pathway of complement might be actively involved in the chronic inflammation in rheumatoid arthritis.
- The mechanism of antiartritic action of glucosamine has been established in patients with osteoarthritis and in a model of collagenase-induced arthritis.
- Elucidation the mode of action of kinase inhibitors – role of neutrophils, key cytokines, chemokines and also RANKL signaling in relation to events leading to osteoclastogenesis in experimental models of rheumatoid arthritis and osteoarthritis.
Projects
2012-2014Б01/6NSF:Application of tyrosin kinase inhibitor tyrphostin AG-490 in a model of collagenase-induced osteoarthritis. PI:Prof. NinaIvanovska.
2014: DО 03-136 – Ministry of Science and Education Program: BG051 PO001/3.3 05 0001 “Science and Business”, Mechanisms of antiinflammaory action of tyrphostin AG490.PI: Asisst. Prof. Valeriya Gyurkovska.
2007-2010 NSF/KT-X-1707: Nuclear factor kappa-(RANKL)-dependent action of glucosamine.PI: Prof. Nina Ivanoska.
Recent publications
Gyurkovska V., Philipov S., Kostova N.,Ivanovska N. Acetylated derivative of glaucine inhibits joint inflammation in collagenase-induced osteoarthritis. Immunopharmacol. Immunotoxicol.,2015 Feb;37(1):56-62. doi: 10.3109/08923973.2014.972414. Epub 2014 Oct 20.
Gyurkovska V., Stefanova T., Dimitrova P., Danova S., Tropcheva R.,Ivanovska N. Tyrosine kinase inhibitor tyrphostin AG490 retards chronic joint inflammation in mice. Inflammation, 37, 2014, 995-1005, ISSN 0360-3997.
Dupont A., Mohamed F., Glenn S., Francescut L., Adib R., Byrne S., Brewin S., Elliott I., Richards L., Dimitrova P., Schwaeble W., Ivanovska N., Kadioglu D., Machado L.R, Andrew P.W.,Stover C. Septicaemia models using Streptococcus pneumoniae and Listeria monocytogenes: understanding the role of complement properdin. Med. Microbiol. Immunol., 2014, 1-15, ISSN 0300-8584.
Gyurkovska V., Stefanova T., Dimitrova P., Danova S., Tropcheva R., Ivanovska N. Tyrosine kinase inhibitor tyrphostin AG490 retards chronic joint inflammation in mice. Inflammation, 37, 2014, 995-1005,ISSN 0360-3997.
Gyurkovska V,Dimitrova P and Ivanovska N. Tyrosine kinase inhibitor TyrphostinAG490 inhibits osteoclast differentiation in collagenase-induced osteoarthritis. Eur. J. Inflam., 2014,12(2): 329-340ISSN: 1721-727X
Georgiev M.I., Ivanovska N., Alipieva K., Dimitrova P.,Verpoorte R. Harpagoside: From Kalahari Desert to pharmacy shelf. Phytochemistry, 92, 2013, 8-15, ISSN 0031-9422.
Dimitrova P., Ivanovska N. Tyrphostins as a promising therapeutic tool in inflammation-related conditions. OA Inflammation 1, 2013, 4. ISSN 2052-787X.
Dimitrova P., Ivanovska N., Belenska L., Milanova V., Schwaeble W., Stover C. Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody-induced arthritis. Arthritis Res. Ther., 2012, 14: R173.
Dimitrova P., Danova S., Ivanovska N. Pro-inflammatory action of Candida albicans DNA in zymosan-induced arthritis. Inflammation Res., 2012, 61: 649-656.ISSN: 1420-908X
Dimitrova P., Kostadinova E., Milanova V., Alipieva K., Georgiev M., and Ivanovska N. Antiinflammatory properties of extracts and compounds isolated from verbascum xanthophoeniceum griseb. Phytotherapy Res., 2012, 26: 1681-1687.ISSN: 1099-1573
Dimitrova P., Toncheva A., Gyurkovska V.,Ivanovska N. Involvement of soluble receptor activator of nuclear factor-κB ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis. Rheumat. Intеrnat., 2012, 32 (5), 1317-1325.ISSN: 0172-8172
Dimitrova P., Georgiev M.I., Khan M.T.H., Ivanovska N. Evaluation of Verbascum species and harpagoside in models of acute and chronic inflammation. Central Eur. J. Biol., 2012, 8: 186-194. ISSN:1895-104X
Stefanova, T., Nikolova, N., Neychev, H., Zlabinger, G. Phagocytosis and killing of Salmonella by 7-hydroxycoumarin activated macrophages. Immunol. Invest., 41, 2012, 199-213. ISSN, 0882-0139. ISSN: 0882-0139
Gyurkovska, V., Alipieva, K., Maciuk A., Dimitrova, P., Haas, C., Bley, T.,Georgiev, M. Anti-inflammatory activity of Devil's claw in vitro systems and their active constituents. Food Chemistry, 125, 2011, 171-178.ISSN: 0308-8146
Ivanovska, N., and P., Dimitrova. Bone resorption and remodeling in murine collagenase-induced osteoarthritis after administration of glucosamine. Arthritis Res. Ther., 2011: 13, R44.
Dimitrova, P., and Ivanovska N. How important are innate immunity cells in osteoarthritis pathology. In: Osteoarthritis. InTech, Rijeka, Croatia, 2011. ISBN: 979-953-307-082-6.
Dimitrova, P., Toncheva, A., Gyurkovska V, Ivanovska N. Involvement of soluble receptor activator of nuclear factor-κB ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis. Rheumatol. Internat.,3, 2011. ISSN: 0172-8172.
Dimitrova, P., Ivanovska, N., Schwaeble, W., Gyurkovska, V., andC, Stover. The role of properdin in murine zymosan-induced arthritis. Mol. Immunol., 2010, 47: 1458-1466.ISSN: 0161-5890.
Stefanova, T.H., Ratcheva, I., Nikolova, N.J., Neychev, H.O.Effect of yeast superoxide dismutase treatment on some mediators of inflammation during adjuvant-induced arthritis in mice.Z Naturforsch C. 2010 Jan-Feb;65(1-2):141-7.
Dimitrova, P., Gyurkovska, V., Shalova, I., Saso, L., Ivanovska, N. Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490. J. Inflam., 2009, 6, 13. ISSN: 1476-9255.
LABORATORY of Experimental Immunology
Head: Associate Professor Andrey Tchorbanov, PhD
Tel: +359 2 979 6357
Email:
Assist. Professor Nikolina Mihaylova, PhD,
Assist. Kalina Nikolova-Ganeva, PhD,
Assist. Nikola Kerekov, PhD student,
Vera Gesheva, PhD student,
Iva Ivanova, PhD student,
Iliyan Manoylov, PhD student,
Silvya Bradyanova, student MSc programme
Petroslav Chepinski, MSc student
Desislava Hlebarska, MSc student
Kiril Valentinov, student
Slav Slavov, student
Neli Delcheva, student
Projects
NFSI – Bulgaria VU 704/07 “New approach for selective suppression of autoreactive B cells by a chimeric anti-CD35 antibody” 2007-2011;Project leader A. Tchorbanov
NFSI – Bulgaria TK 317/07 “Generation of gene-engineered chimeric DNA molecules by recombinant technologies for specific therapy of autoimmune diseases” 2007-2011; PI: A. Tchorbanov
NFSI – BulgariaVUH 11/07 “Creation of engineered chimeric molecules by protein nano-technology for therapy of autoimmune diseases” 2007-2011; PI: A. Tchorbanov
Bulgarian-Hungarian international join project “Genetically engineered viral DNA vaccines” 2010-2013; PI: A. Tchorbanov
NFSI – Bulgaria DO 312/08 “Suppression of allergen-specific B lymphocytes in humanized SCID mice using Chimeric protein-engineered antibodies”2008-2012; PI: A. Tchorbanov
NFSI – Bulgaria DRNF 02/11 “Biologic response of neoplastic and auto-immune B-cells to chimeric protein-engineered antibodies: flow cytometry analysis of apoptosis using novel cyanine nucleic acid dyes”2009-2012; PI:P. Dimitrova
NFSI – Bulgaria DTK 02/19 “DNA vaccines: Viral Antigen Targeting by Genetically Engineered Chimeric Molecules”2010-2015; PI: A. Tchorbanov
NFSI – Bulgaria DTK 02/78 “Antitumor activity of Gastropodan hemocyanins” Running; 2010-2014; PI: A. Tchorbanov
NFSI – Bulgaria DVU 10-250 “Functional elimination of autoreactive T cells by antibody therapy in murine and humanized SCID models of Systemic lupus erythematosus and Multiple sclerosis” 2011-2015;PI: A. Tchorbanov
ACIP - ACTIONS CONCERTEES INTERPASTEURIENNES. „Viral Antigen Targeting by Genetically Engineered Chimeric Molecules”2013-2015;PI: A. Tchorbanov
Bulgarian-Hungarian international join project “Functional suppression of autoreactive T cells in murine and humanized SCID models of SLE” 2013-2015; PI: A. Tchorbanov
Recent publications
Nikolova K., Mihaylova N., Voynova E., Kerekov N., Gesheva V., Prechl J., NikolovaM., Tchorbanov A. Re-establishing tolerance to DNA in humanized and murine models ofSLE. AutoimmunRev 2010, 9, 499–502.ISSN: 1568-9972
Dimitrova I., Gesheva V., Nikolova K., Mihaylova N., Todorov T., Nikolova M. Tchorbanov A. Target silencing of disease-associated B-lymphocytes by chimericmolecules in SCID model of pristane-induced autoimmunity. Lupus 2010, 19(11), 1261-1271. ISSN: 1477-0962
Nikolova K., Mihaylova N., Voynova E., Tchorbanov A., Voll R., Vassilev T. Selective silencing of autoreactive B lymphocytes – following the Nature’s way. AutoimmunRev 2010, 9, 775-779.ISSN: 1568-9972.
Papp K., Végh P., TchorbanovA., VassilevT., Erdei A., Prechl J. Progression of the SLE-like disease drives the appearance of complement activating IgG antibodies in MRL/lpr mice. Rheumatology2010, 49(12),2273-2280.ISSN: 1568-9972
GeshevaV., Idakieva K.,Kerekov N., Nikolova K.,Mihaylova N., Doumanova L.,Tchorbanov A. Marine gastropod hemocyanins as adjuvants of non-conjugated bacterial and viral proteins. Fish and Shellfish Immunol 2011, 30 (1), 135-142. ISSN:1050-4648.
Kaloyanova S., Ivanova I., Tchorbanov A., Dimitrova P., Deligeorgiev T.Synthesis of chloro-substituted analogs of Thiazole Orange - fluorophores for flow cytometric analyses. J Photochem Photobiol B: Biology 2011, 103, 215–221.ISSN: 1011-1344
GeshevaV., Idakieva K.,Kerekov N., Nikolova K.,Mihaylova N., Doumanova L.,Tchorbanov A. Rapana Thomasiana hemocyanin as adjuvant for conventional vaccines. Adv Bulgarian Science 2011, 21-29. ISSN1312-6164
Kerekov N., Mihaylova N., Prechl J., Tchorbanov A. Humanized SCID Mice Models of SLE. Curr Pharmaceutical Design 2011, 17(13),1261-1266.ISSN: 1873-4286
MihaylovaN., Tchorbanov A. Selective Immunotherapy by engineered chimeric molecules. Acta Facultatis Medicae Naissensis 2011, 28(1), 5-15.ISSN: 2217-2521
Kerekov N.,Mihaylova N.,Grozdev I., Todorov T., Nikolova M., Baleva M., Nikolova M.,Prechl J., ErdeiA., TchorbanovA. Elimination of autoreactive B cells in humanized SCID mouse model of SLE. EurJImmunol 2011, DOI 10.1002/eji.201141439. ISSN:1521-4141
Petkova, S., Nikolova, K., Mihaylova N., Tchorbanov A. Characterization of chimeric molecules that suppress selectively autoreactive B-cells in murine models of lupus. Proceedings, Youth Scientific conference “Kliment’s days”, Sofia, 2011, ISSN: 1314 – 4960; 49-52.
MihaylovaN., Tchorbanov A. New biotechnology approaches for immunotherapy of autoimmune diseases. Biotechnol Biotechnol Eq 2011, 25/4, 24-29. ISSN: 1310-2818
Gesheva V., Idakieva K., Doumanova L., Tchorbanov A. Anti-cancer properties of Rapana thomasiana hemocyanin in experimental models in vitro and in vivo. Здраве и наука 2012, 2(5), 30-34. ISSN1314-2674
Gesheva V., Szekeres Z.,MihaylovaN.,Dimitrova I., Nikolova M., ErdeiA., Prechl J., TchorbanovA. Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases. Human Gene Therapy Methods 2012, 23(6): 357-365.ISSN: 1557-7422
Nikolova, K., Kaloyanova, S., Mihaylova, N., Stoitsova, S., Chausheva, S., Vasilev, A., Lesev, N., Dimitrova, P., Deligeorgiev, T., Tchorbanov, A. New fluorogenic dyes for analysis of cellular processes by flow cytometry and confocal microscopy. J Photochem Photobiol B: Biology 2013, 129: 125-134. DOI 10.1016/j.photobiol.2013.10.010. ISSN: 1011-1344
Djoumerska-AlexievaI., ManoylovI., Dimitrov J., TchorbanovA. Serum or breast milk immunoglobulins mask the self-reactivity of human natural IgG antibodies. APMIS 2014, 122: 329–340; DOI 10.1111/apm.12149.ISSN: 1600-0463
Kerekov N.,MichovaA., Muhtarova M., Nikolov G., Mihaylova N.,PetrunovB., Nikolova M.,TchorbanovA. Suppression of allergen-specific B lymphocytes by chimeric protein-engineered antibodies. IMBIO 2014, 219(1): 45–52; DOI 10.1016/j.imbio.2013.07.009.ISSN: 0171-2985
Gesheva V., Kerekov N., Nikolova, K., MihaylovaN., Todorov T., Nikolova M., TchorbanovA. Suppression of dsDNA-specific B Lymphocytes reduces disease symptoms in SCID model of mouse lupus. Autoimmunity 2014, 6;47(3):162-72; DOI: 10.3109/08916934.2014.883502.ISSN: 1568-9972
Kerekov N., IvanovaI., Mihaylova N.,Nikolova M.,Prechl J., TchorbanovA. Built-in adjuvanticity of Genetically and Protein Engineered Chimeric Molecules for Targeting of Influenza A peptideepitopes. Immunol Research 2014, 60(1), 23-34; DOI 10.1007/s12026-014-8489-0.ISSN: 0257-277X
Birner P., Pusch S., Christov C., Mihaylova S., Toumangelova-Uzeir K., Natchev S., Schoppmann S.F., Tchorbanov A., Wesseling P., Streubel B., Tuettenberg J., Guentchev M. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer 2014, 120 (16), 2440-2447; DOI:10.1002/cncr.28732.ISSN: 1097-0142
Gesheva V., Chausheva S., Mihaylova N., Manoylov I.,Doumanova L., Idakieva K., Tchorbanov A. Anti-cancer properties of gastropodan hemocyanins in murine model of coloncarcinoma. BMC Immunology2014, 15:34, DOI: 10.1186/s12865-014-0034-3.ISSN: 1471-2172
LABORATORY of Experimental Immunotherapy
Head:Associate Professor Anastas Pashov, PhD
е-mail:
Prof. Tchavdar Vassilev, M.D., Ph.D.,
Assoc. Prof. Petya Dimtrova, Ph.D.,
Assistant Prof. Iglika Djoumerska-Alexieva. M.D., Ph.D.,
Ph.D. Student Maya Hadjieva
Main research topics
Novel immunotherapeutics based on intravenous immunoglobulins
Immunotherapy of sepsis,
Immunotherapy of inflammatory and degenerative tissue damage,
Immunogenicity of biopharmaceuticals,
Development of biomarkers based on system analysis of the antibody repertoire
Most important results
- Using a method for modification of IgG specificity patented by us, we developed a pooled human immunoglobulin preparation for intravenous use with an enhanced anti-inflammatory effect. Unlike the commercial preparations (IVIg), their modified variants exert a powerful immunotherapeuticeffect in sepsis models. The mechanisms of action of the modified IVIg cannot be reduced to individual antibody specificity, antibacterial action, a single factor or isolated signaling path. Instead, our studies showed multiple effects including increased reactivity with some cytokines, complement components, molecular structures recognized as “danger signals”, etc.Thus, the effect of modified IVIg is better characterized as systemic and seems to offer a model, the studies on which could outline a new system immunology paradigm. It would trigger the development of a new class of immunotherapies related to the fast growing field of the system biology and, probably, offer anovel and efficient strategy for the treatment of sepsis.
- Applying a system biology approach to the antibody repertoire studies, we develop diagnostic methods based on the signatures in a large number of antibody reactivities (103- 104)used as biomarkers in a broad nosology spectrum. To this end, microarrays are designed, which contain 4000 -10000 diverse peptides selected among known B cell epitopes together with their homologues, diversified according an in house bioinformatic algorithms, as well as complete library of tripeptides in a pharmacophore like analysis.
- Studying the approaches to alter functions of neutrophils and their interaction with immune or tissue-specific cells as a tool for tissue repair modulation in a variety of pathologies and disorders.
- Bioinformatic algorithms are being developed for the prediction of the risk of inhibitory anti-drug antibody elicitation during treatment with biopharmaceuticals. Factor VIIIof the coagulation cascade was used as a model whereby the immunogenicity of the protein is considered in the context of the HLA haplotype of the patient. The design of another algorithm for “deimmunization” of biopharmaceuticals is ongoing too. It is based on mutations that destroy the immunogenic epitopes but preserve the function.
- In a study on the capacity of different B cell populations in the mouse to modify the phenotype of co-stimulated T cellsa potential regulatory role was found for the T1 splenic B cell population as well as for the B cells withpolyspecific B cell receptor after suboptimal stimulation with broadly cross-reacting epitope - fluorescein. A correlation was found between the immunotherapeutic effects of the modified immunoglobulins and the stimulation of B celss with the phenotype of plasmablasts from the B1 population (allegedly innate response activators secreting GM-CSF).
Projects
2015-2017 National Fund “Scientific Research”. B 02/275 Physiological roleand therapeutic potential of antibodies with induced polyspecificity. PI: Prof. Tchavdar Vassilev
2012-2015 SNSF IZEBZO_142967: Design of modified immunoglobuin preparations with induced polyspecificity for passive immunotherapy of sepsis, Prof. Tchavdar Vassilev.
2012-2014: ACIP A07-2012: Therapeutic potential of modified pooled IgM and IgG preparations in experimental severe inflammatory response syndrome (SIRS) and sepsis, PI: Prof. Tchavdar Vassilev
2007-2013: BG 051 PO001-3.3.04/32: Operational Programme "Human Resources Development", co-financed by the European Social Fund of the European Union: Effective training of students and career development of post-docs and young researchers in priority areas of microbiology”. Lector in the Module Immunology: PI: Assoc. Prof. Petya Dimitrova2010-2013 Marie Curie International Re-integration Grants (IRG), FP7-PEOPLE-2009-RG 248289. Translational study on the antigen presenting properties of human vs mouse B cell subpopulations, PI: Assoc. Prof. Anastas Pashov
2011-2013 ACIP/A05_11: The role of neutrophils and NK cells in the development of collagenase-induced osteoarthritis, PI: Assoc. Prof. Petya Dimitrova, Institute of Microbiology-Sofia, Co-PI: Prof. Angela Santoni University La Sapienza-Rome, Co-PI: Crina Stavaru, Cantacuzino Institute-Bucharest.
2012: DО2 538/20.06.2012 - Ministry of Science, Youth and Education Program: BG051 PO001/3.3 05 0001 “Science and Business”, Support of specialized publications in refereed journals with impact factor: Abrogated RANKL expression in properdin-deficient mice is associated with better outcome from collagen-antibody-induced arthritis). PI: Assoc. Prof. Petya Dimitrova.
Recent publications
Von Gunten S, Shoenfeld Y, Blank M, Branch DR, Vassilev T, Käsermann F, Bayry J, Kaveri S, Simon HU. 2014,IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Rev.Immunol,14, 349-350.
Pavlovic, S., Zdravkovic, N., Peijnovic, N., Djoumerska-Alexieva, I., Arsenjevic, N., Vassilev, T., Lukic, M. Enhanced anti-diabetogenic effect of intreavenous immune globulin modified by ferrous ion exposure. Eur.J.Inflamm. 2014: 12, 67-76, ISSN 1721-727X
Lecerf M, Scheel T, Pashov AD, Jarossay A, Ohayon D, Planchais C, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. 2015. Prevalence and Gene Characteristics of Antibodies with Cofactor-induced HIV-1 Specificity. Journal of Biological Chemistry
Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, Miescher S, Simon H-U, Pashov A, Vassilev T, von Gunten S. 2015. The human IgG anti-carbohydraterepertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Science Translational Medicine 7: 269ra1
Kieber-Emmons T, Saha S, Pashov A, Monzavi-Karbassi B, Murali R. 2014. Carbohydrate-mimetic peptides for pan anti-tumor responses. Front Immunol 5: 308
Saha S, Pashov A, Siegel ER, Murali R, Kieber-Emmons T. 2014. Defining the recognition elements of lewis y-reactive antibodies. PLoS One 9: e104208
Pashova S, Dobrev K, Pashov A. 2014. Rregulatory Properties of Mouse Transitional 1 B Lymphocytes. Comptes rendus de l'Academie bulgare des Sciences 67: 361-6
Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT. 2014. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol 25: 2053-65
Pashov AD, Calvez T, Gilardin L, Maillere B, Repesse Y, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S. 2014. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia 20: 176-84
Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. 2013. Tumor-Associated Glycans and Immune Surveillance. Vaccines 1: 174-203
Djoumerska-Alexieva I, Pashova S, Vassilev T, Pashov A. 2013. The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 12: 653-6
Kieber-Emmons T, Monzavi-Karbassi B, Pashov A, Saha S, Murali R, Kohler H. 2012. The promise of the anti-idiotype concept. Front Oncol 2: 196
Hennings L, Artaud C, Jousheghany F, Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. 2011. Carbohydrate Mimetic Peptides Augment Carbohydrate-Reactive Immune Responses in the Absence of Immune Pathology. Cancers 3: 4151-69
Pashov A, Delignat S, Bayry J, Kaveri SV. 2011. Enhancement of the Affinity of Glucocorticoid Receptors as a Mechanism Underlying the Steroid-sparing Effect of Intravenous Immunoglobulin. The Journal of Rheumatology 38: 2275
Pashov A, Monzavi-Karbassi B, Raghava GP, Kieber-Emmons T. 2010. Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol 2010: 354068
Pashov A, Monzavi-Karbassi B, Kieber-Emmons T. 2011. Glycan mediated immune responses to tumor cells. Hum Vaccin 7: 156-65
Pashov A, Garimalla S, Monzavi-Karbassi B, Kieber-Emmons T. 2009. Carbohydrate targets in HIV vaccine research: lessons from failures. Immunotherapy 1: 777-94
Dimitrov JD, Planchais C, Kang J, Pashov A, Vassilev TL, Kaveri SV, Lacroix-Desmazes S. 2010. Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochemical and Biophysical Research Communications 398: 266-71
Todorova VK, Klimberg VS, Hennings L, Kieber-Emmons T, Pashov A. 2010. Immunomodulatory effects of radiofrequency ablation in a breast cancer model. Immunol Invest 39: 74-92